viewImmuPharma PLC

ImmuPharma continuing to talk with potential partners

The drug developer is assessing the best route forward for its lead drug, a treatment for the autoimmune disease, Lupus

clinical trial written on a pad
The results of an extension study of Lupuzor are due soon

ImmuPharma PLC (LON:IMM) has confirmed that discussions with potential partners are ongoing as it assess the best route forward for its lead drug.

The results from an extension study of Lupuzor, a treatment for the autoimmune disease Lupus, will feed into the decision making.

WATCH: Immupharma PLC assessing best route forward for lead drug Lupuzor

A readout from the clinical assessment of 62 patients who took part in an earlier phase III trial is expected later this current quarter, the firm confirmed in an update alongside its full-year results.

The results of that final-phase assessment of Lupuzor were inconclusive, but ImmuPharma believes the drug has a part to play in the treatment regimen of sufferers. Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.

Managed access programme on hold 

A planned managed access programme that would have provided patients with Lupuzor even though it doesn’t yet have regulatory sign-off has been put on hold.

This is to allow management to discuss with potential corporate partners and regulatory advisors the best way forward.

In the meantime, the company will focus on other applications in the autoimmune space for the drug, which is also known as P140.

ImmuPharma previously announced plans to merge its Elro and Ureka subsidiaries and it confirmed Friday it will look to out-licence their technologies, or spin off the businesses completely. This would allow the AIM-listed drug developer to concentrate on P140.

Results for the year ended December 31 showed the company posted a £7.2mln loss. More important to followers and would-be investors is cash in the bank, which was £4.9mln at the period-end. The coffers were topped up following a £10mln fundraiser in January.

Quick facts: ImmuPharma PLC

Price: 13 GBX

Market: AIM
Market Cap: £32.53 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...


ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

on 25/11/20

2 min read